{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T06:32:46Z","timestamp":1726036366476},"reference-count":40,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2014,3,17]],"date-time":"2014-03-17T00:00:00Z","timestamp":1395014400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0091644","type":"journal-article","created":{"date-parts":[[2014,3,17]],"date-time":"2014-03-17T16:41:04Z","timestamp":1395074464000},"page":"e91644","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["The Expression of Ribonucleotide Reductase M2 in the Carcinogenesis of Uterine Cervix and Its Relationship with Clinicopathological Characteristics and Prognosis of Cancer Patients"],"prefix":"10.1371","volume":"9","author":[{"given":"Ying-Fang","family":"Su","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tzu-Fan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiunn-Liang","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsiu-Ting","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Torng","family":"Tee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Hsien","family":"Chien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Hung","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wea-Lung","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui-Ying","family":"Low","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Yung","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun-Fa","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2014,3,17]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2174\/156800906777723949","article-title":"Ribonucleotide reductase inhibitors and future drug design","volume":"6","author":"J Shao","year":"2006","journal-title":"Curr Cancer Drug Targets"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.cell.2012.03.043","article-title":"Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair","volume":"149","author":"V D'Angiolella","year":"2012","journal-title":"Cell"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/1040-8428(95)00187-5","article-title":"Ribonucleotide reductase inhibitors: new strategies for cancer chemotherapy","volume":"22","author":"G Nocentini","year":"1996","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref4","first-page":"4304","article-title":"Ribonucleotide reductase subunit one as gene therapy target: commentary re: M-Y. Cao et al., Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma","volume":"9","author":"Y Yen","year":"2003","journal-title":"Clin Cancer Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/B978-0-12-386931-9.00014-3","article-title":"The structural basis for the allosteric regulation of ribonucleotide reductase","volume":"117","author":"MF Ahmad","year":"2013","journal-title":"Prog Mol Biol Transl Sci"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1158\/1078-0432.CCR-06-2218","article-title":"Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo","volume":"13","author":"JD Heidel","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"15174","DOI":"10.1074\/jbc.M111.308023","article-title":"Progesterone and DNA damage encourage uterine cell proliferation and decidualization through up-regulating ribonucleotide reductase 2 expression during early pregnancy in mice","volume":"287","author":"W Lei","year":"2012","journal-title":"J Biol Chem"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"17747","DOI":"10.1074\/jbc.M000799200","article-title":"Controlled protein degradation regulates ribonucleotide reductase activity in proliferating mammalian cells during the normal cell cycle and in response to DNA damage and replication blocks","volume":"275","author":"A Chabes","year":"2000","journal-title":"J Biol Chem"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","article-title":"Cisplatin: mode of cytotoxic action and molecular basis of resistance","volume":"22","author":"ZH Siddik","year":"2003","journal-title":"Oncogene"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"8285","DOI":"10.1074\/jbc.271.14.8285","article-title":"Reaction mechanism of human DNA repair excision nuclease","volume":"271","author":"D Mu","year":"1996","journal-title":"J Biol Chem"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"5776","DOI":"10.1128\/MCB.24.13.5776-5787.2004","article-title":"The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks","volume":"24","author":"LJ Niedernhofer","year":"2004","journal-title":"Mol Cell Biol"},{"key":"ref12","first-page":"959","article-title":"Excision repair cross complementing-group 1: gene expression and platinum resistance","volume":"14","author":"R Altaha","year":"2004","journal-title":"Int J Mol Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ijgo.2009.02.012","article-title":"Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium","volume":"105","author":"S Pecorelli","year":"2009","journal-title":"Int J Gynaecol Obstet"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1002\/ijc.25936","article-title":"Implication of human nonmetastatic clone 23 Type 1 and its downstream gene lipocalin 2 in metastasis and patient&apos;s survival of cancer of uterine cervix","volume":"129","author":"PH Wang","year":"2011","journal-title":"Int J Cancer"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa060570","article-title":"DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy","volume":"355","author":"KA Olaussen","year":"2006","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.bjc.6602678","article-title":"REporting recommendations for tumour MARKer prognostic studies (REMARK)","volume":"93","author":"LM McShane","year":"2005","journal-title":"Br J Cancer"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/j.1365-2559.2010.03725.x","article-title":"Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer","volume":"57","author":"T Morikawa","year":"2010","journal-title":"Histopathology"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ajog.2008.01.005","article-title":"Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis","volume":"198","author":"RJ Kurman","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1476-4598-8-11","article-title":"Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis","volume":"8","author":"K Zhang","year":"2009","journal-title":"Mol Cancer"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1124\/mol.111.074708","article-title":"Reduced level of ribonucleotide reductase R2 subunits increases dependence on homologous recombination repair of cisplatin-induced DNA damage","volume":"80","author":"ZP Lin","year":"2011","journal-title":"Mol Pharmacol"},{"key":"ref21","first-page":"1650","article-title":"The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation","volume":"58","author":"H Fan","year":"1998","journal-title":"Cancer Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.humpath.2010.06.001","article-title":"Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro","volume":"41","author":"T Morikawa","year":"2010","journal-title":"Hum Pathol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.cell.2011.03.044","article-title":"Nucleotide deficiency promotes genomic instability in early stages of cancer development","volume":"145","author":"AC Bester","year":"2011","journal-title":"Cell"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"10796","DOI":"10.1074\/jbc.M312482200","article-title":"S Phase-specific transcription of the mouse ribonucleotide reductase R2 gene requires both a proximal repressive E2F-binding site and an upstream promoter activating region","volume":"279","author":"AL Chabes","year":"2004","journal-title":"J Biol Chem"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3816\/CCC.2007.n.007","article-title":"Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer","volume":"6","author":"X Liu","year":"2007","journal-title":"Clin Colorectal Cancer"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1101\/gad.1863810","article-title":"Essential role of Tip60-dependent recruitment of ribonucleotide reductase at DNA damage sites in DNA repair during G1 phase","volume":"24","author":"H Niida","year":"2010","journal-title":"Genes Dev"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"18085","DOI":"10.1074\/jbc.M109.003020","article-title":"Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response","volume":"284","author":"YW Zhang","year":"2009","journal-title":"J Biol Chem"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.bbrc.2006.12.177","article-title":"RRM2 induces NF-kappaB-dependent MMP-9 activation and enhances cellular invasiveness","volume":"354","author":"MS Duxbury","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/sj.bjc.6604344","article-title":"Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel\/gemcitabine","volume":"98","author":"J Souglakos","year":"2008","journal-title":"Br J Cancer"},{"key":"ref30","first-page":"21","article-title":"Cellular signaling pathways affect the function of ribonucleotide reductase mRNA binding proteins: mRNA stabilization, drug resistance, and malignancy (Review)","volume":"22","author":"TR Burton","year":"2003","journal-title":"Int J Oncol"},{"key":"ref31","first-page":"2151","article-title":"Overexpression of catalytic subunit M2 in patients with ovarian cancer","volume":"125","author":"LM Wang","year":"2012","journal-title":"Chin Med J"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"7094","DOI":"10.1038\/sj.onc.1208854","article-title":"Identification of a proliferation gene cluster associated with HPV E6\/E7 expression level and viral DNA load in invasive cervical carcinoma","volume":"24","author":"C Rosty","year":"2005","journal-title":"Oncogene"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1042\/CS20120240","article-title":"Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers","volume":"124","author":"X Liu","year":"2013","journal-title":"Clin Sci"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/0090-8258(90)90072-S","article-title":"Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study","volume":"38","author":"G Delgado","year":"1990","journal-title":"Gynecol Oncol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/0090-8258(89)90598-2","article-title":"Determinants of increased risk for recurrence in patients undergoing radical hysterectomy for stage IB and IIA carcinoma of the cervix","volume":"33","author":"AF Fuller Jr","year":"1989","journal-title":"Gynecol Oncol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1002\/1097-0142(19951115)76:10+<1978::AID-CNCR2820761313>3.0.CO;2-K","article-title":"Prognostic factors of early stage cervical cancer treated by radical hysterectomy","volume":"76","author":"BU Sevin","year":"1995","journal-title":"Cancer"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.ajog.2008.04.028","article-title":"Combined adverse effect of African American race and deep stromal invasion on survival following radical hysterectomy for cervical cancer","volume":"199","author":"H Sapp","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1006\/gyno.1999.5420","article-title":"Tumor size, depth of invasion, and grading of the invasive tumor front are the main prognostic factors in early squamous cell cervical carcinoma","volume":"74","author":"GB Kristensen","year":"1999","journal-title":"Gynecol Oncol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/cncr.11269","article-title":"Histopathologic score predicts recurrence free survival after radical surgery in patients with stage IA2-IB1-2 cervical carcinoma","volume":"97","author":"DA Grisaru","year":"2003","journal-title":"Cancer"},{"key":"ref40","first-page":"101","article-title":"Ribonucleotide reductase inhibitors as anticancer and antiviral agents","volume":"31","author":"EJ Lien","year":"1987","journal-title":"Prog Drug Res"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0091644","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T03:50:15Z","timestamp":1540007415000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0091644"}},"subtitle":[],"editor":[{"given":"Chih-Hsin","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,3,17]]},"references-count":40,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,3,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0091644","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,17]]}}}